Results for this period
Full year1 April 2025–31 March 2026ConsolidatedU.S. GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased mainly in bio CDMO, semiconductor materials and imaging. Electronics benefited from demand for AI semiconductors and strong sales of semiconductor materials, while imaging benefited from growth in instax and digital camera sales. Healthcare reported lower profit despite higher revenue, and business innovation reported lower revenue and profit due to weak market conditions and declining sales, among other factors.
No applicable matters. The filing states, "There are no applicable matters."
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | U.S. GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥3,356,969 million (YoY +5.0%) |
| Operating profit | ¥350,210 million (YoY +6.1%) |
| Profit attributable to owners of the parent | ¥276,735 million (YoY +6.0%) |
| Net income per share | ¥229.65 |
| Operating Margin | 10.4% |
| Equity ratio | End of the current fiscal period 63.4% / End of previous period 63.8% |
| Total assets | ¥6,053,776 million |
| Net assets | ¥3,844,385 million |
| Cash flows from operating activities | ¥410,555 million |
| Cash flows from investing activities | ¥-554,604 million |
| Cash flows from financing activities | ¥120,249 million |
| Cash and cash equivalents at end of period | ¥170,553 million |
| Full-year earnings forecast | Net Sales ¥3,470,000 million (YoY +3.4%) / Operating profit ¥365,000 million (YoY +4.2%) / Ordinary income Not disclosed / Net income ¥280,000 million (YoY +1.2%) |
| Annual Dividend Forecast | ¥70 → ¥75（+7.1%） |
| Payout ratio | 30.5% (current fiscal year actual), 32.0% (next fiscal year forecast) |
| Shareholder Return Policy | Maintain a payout ratio of approximately 30% as a guideline, and make flexible share repurchases after taking cash flow into consideration |
| Segment revenue | Healthcare ¥1,098,925 million (YoY +4.9%), Electronics ¥456,157 million (YoY +11.9%), Business Innovation ¥1,174,800 million (YoY -2.0%), Imaging ¥627,087 million (YoY +15.7%) |
| Segment profit | Healthcare ¥63,637 million (YoY -20.3%), Electronics ¥100,883 million (YoY +34.4%), Business Innovation ¥63,712 million (YoY -14.6%), Imaging ¥160,003 million (YoY +14.9%) |
| Regional sales | ¥1,168,682 million (YoY +6.3%), ¥657,898 million (YoY +1.7%), ¥581,133 million (YoY +6.7%), ¥949,256 million (YoY +4.9%) |
| Depreciation and amortization | ¥172,371 million |
| Disclosure regarding the going concern assumption | No applicable matters. The filing states, "There are no applicable matters." |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Not disclosed / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (no attendees specified) |
| Issued Shares at Period-End | 1,243,877,184 Shares |
| Treasury Shares at Period-End | 38,547,368 Shares |
| Factors Behind Changes in Business Performance | Revenue increased mainly in bio CDMO, semiconductor materials and imaging. Electronics benefited from demand for AI semiconductors and strong sales of semiconductor materials, while imaging benefited from growth in instax and digital camera sales. Healthcare reported lower profit despite higher revenue, and business innovation reported lower revenue and profit due to weak market conditions and declining sales, among other factors. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased mainly in bio CDMO, semiconductor materials and imaging. Strong sales in electronics and imaging, as well as demand for AI semiconductors and growth in instax and digital camera sales, contributed to the increase, while healthcare and business innovation reported lower profits.